$15m cap raise Fresh Equities at 24c, page-553

This is fair assessment. I’m personally happy with my investment risk here as the newly released proteomics sheds light on a well known adjacency pathway (think phosphokinase pi3k regulation in precision oncology etc.) in relation to the growth factors and precursory peptides that ATL1102 seems to regulate. A larger cohort size with a higher dose stratum should yield some interesting results. I do agree that the most exciting take away from the P2A is the maintenance or improvement in test scores amongst the majority of subjects.